Daniel Furst
Daniel E. Furst is the first Carl M. Pearson Professor of Medicine at the University of California, Los Angeles (UCLA), Medical Center, David Geffen School of Medicine, Department of Medicine, Division of Rheumatology. Dr. Furst received his MD from Johns Hopkins University, where he also completed his internship and residency. He completed two fellowships, one in Rheumatology at UCLA Medical Center, and a second in clinical pharmacology at the University of California, San Francisco Medical Center.
After serving as assistant professor of medicine/rheumatology at the UCLA Medical Center and associate professor of internal medicine/Rheumatology at the University of Iowa Carver College of Medicine, Dr. Furst became clinical professor in the Department of Medicine, Division of Rheumatology and Connective Tissue Research at the University of Medicine and Dentistry of New Jersey, and director of AI/P Clinical Research at Ciba Geigy Pharmaceuticals. He then moved to Seattle, where he was clinical professor of medicine at the University of Washington, then director of clinical research programs and director of the Arthritis Clinical Research Unit at the Virginia Mason Medical Center. He then took up his present position at UCLA.
Dr. Furst has been on a number of national committees concerned with rheumatic therapeutics, including as a member and Fellow in the American College of Rheumatology and The American Society of Clinical Pharmacology and Therapeutics. He has also been a member of the Arthritis Advisory Committee for the FDA. He was Chairman of the Innovative Therapies Meeting of the American College of Rheumatology and Clinical Abstracts Selection Chair for the National American College of Rheumatology meeting. He recently was co-leader of the ACR recommendations for the use of non-biologic and biologic therapies in RA. He has served or is serving on the editorial boards of Inpharma, Clinical Drug Investigation, Drugs, The Journal of Clinical Rheumatology, and The Journal of Rheumatology. Additionally, he is an editorial reviewer for professional publications including Arthritis & Rheumatism, The New England Journal of Medicine, Journal of Clinical Investigation, Pharmacotherapy and the Annals of the Rheumatic Diseases.Dr. Furst has published more than 450 articles and 14 books, including more than 220 research articles and more than 230 reviews or chapters in addition to two editions of a book on scleroderma. Dr. Furst’s areas of research interest include the clinical pharmacology of anti-rheumatic drugs and biologics, and the pathophysiology and treatment of systemic sclerosis.
